Nexalin Technology’s Groundbreaking Study on Deep Intracranial Frequency Stimulation (DIFS)
Houston, TX, February 3, 2025 – Nexalin Technology, Inc., a pioneering company in the field of Deep Intracranial Frequency Stimulation (DIFS), has recently published a landmark study in the prestigious Journal of Affective Disorders. This study highlights the potential of Nexalin’s proprietary DIFS technology to bring about significant reductions in both systolic and diastolic blood pressure in patients diagnosed with Major Depressive Disorder (MDD).
DIFS: A Non-Invasive Approach to Addressing Depression and Blood Pressure
The study, which was conducted over a period of six months, involved a randomized, double-blind, sham-controlled trial. The researchers found that patients who underwent DIFS treatment experienced a notable decrease in their blood pressure levels. These reductions were not observed in the control group, which received a placebo treatment. This finding is particularly significant because MDD is known to be associated with increased risk for cardiovascular diseases, including hypertension.
DIFS: A New Hope for Depression and Cardiovascular Health
The results of this study could potentially pave the way for a new, non-invasive approach to treating both depression and related cardiovascular issues. Traditional methods for managing these conditions often involve medication or invasive procedures, which can come with a range of side effects and complications. DIFS, on the other hand, is a non-invasive, pain-free treatment that is administered through a small, implantable device.
DIFS: A Potential Game-Changer for the Healthcare Landscape
- According to the World Health Organization, more than 300 million people worldwide suffer from depression. With the potential to offer relief for those dealing with both depression and cardiovascular issues, DIFS could significantly impact the lives of millions.
- The global market for depression treatments is projected to reach $22.1 billion by 2026. The introduction of an effective, non-pharmacological treatment like DIFS could disrupt this market and offer a more accessible, affordable alternative.
- The use of DIFS technology could also extend beyond the treatment of depression and cardiovascular issues. Research suggests that it may have applications in the management of various neurological conditions, such as Parkinson’s disease, epilepsy, and chronic pain.
DIFS: A New Era in Brain Health
This groundbreaking study marks an important step forward in our understanding of the brain and its potential to be harnessed for therapeutic purposes. As research in the field of neurostimulation continues to advance, we can expect to see more innovative applications and treatments that will revolutionize the way we approach mental and physical health.
Conclusion
The publication of Nexalin Technology’s study on Deep Intracranial Frequency Stimulation (DIFS) in the Journal of Affective Disorders represents a significant milestone in the field of neurostimulation. The findings suggest that DIFS has the potential to offer meaningful reductions in blood pressure for patients with Major Depressive Disorder, while providing a safe, non-invasive approach to addressing both depression and related cardiovascular challenges. This could mark the beginning of a new era in brain health, with far-reaching implications for the healthcare landscape and the lives of millions of people around the world.
As we continue to explore the potential of DIFS and other forms of neurostimulation, we can look forward to a future where mental and physical health are not only better understood but also more accessible and affordable for all.
Stay tuned for more updates on this exciting development in the world of neuroscience and healthcare!
